BGT226

TargetMol
Product Code: TAR-T6072L
Supplier: TargetMol
CodeSizePrice
TAR-T6072L-1mg1mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6072L-5mg5mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6072L-1mL1 mL * 10 mM (in DMSO)£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6072L-10mg10mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6072L-25mg25mg£418.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6072L-50mg50mg£583.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6072L-100mg100mg£787.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Bgt226 is a novel dual PI3K / mTOR inhibitor, it acts on PI3K α/β/γ with IC50 of 4 nM / 63 nM / 38 nM, respectively.
CAS:
915020-55-2
Formula:
C28H25F3N6O2
Molecular Weight:
534.543
Pathway:
Autophagy; PI3K/Akt/mTOR signaling
Purity:
0.9574
SMILES:
COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1
Target:
PI3K; mTOR; Autophagy

References

Baumann P , Schneider L , Mandl-Weber S , et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.[J]. Anticancer Drugs, 2012, 23(1):131-138. Markman B , Tabernero J , Krop I , et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors[J]. Annals of Oncology Official Journal of the European Society for Medical Oncology, 2012, 23(9):2399. 2. Chang K Y , Tsai S Y , Wu C M , et al. Novel Phosphoinositide 3-Kinase/mTOR Dual Inhibitor, NVP-BGT226, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo[J]. Clinical Cancer Research, 2011, 17(22):7116-7126.